BR112022017578A2 - Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo - Google Patents
Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmoInfo
- Publication number
- BR112022017578A2 BR112022017578A2 BR112022017578A BR112022017578A BR112022017578A2 BR 112022017578 A2 BR112022017578 A2 BR 112022017578A2 BR 112022017578 A BR112022017578 A BR 112022017578A BR 112022017578 A BR112022017578 A BR 112022017578A BR 112022017578 A2 BR112022017578 A2 BR 112022017578A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxetan
- fluorobenzyl
- overweight
- piperidin
- pyridin
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 3
- 206010033307 Overweight Diseases 0.000 title abstract 3
- 235000020824 obesity Nutrition 0.000 title abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- -1 4-CYANO-2-FLUOROBENZYL Chemical class 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HYBAKUMPISVZQP-DEOSSOPVSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HYBAKUMPISVZQP-DEOSSOPVSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000787P | 2020-03-27 | 2020-03-27 | |
| US202063126113P | 2020-12-16 | 2020-12-16 | |
| US202163135870P | 2021-01-11 | 2021-01-11 | |
| PCT/IB2021/052430 WO2021191812A1 (en) | 2020-03-27 | 2021-03-24 | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017578A2 true BR112022017578A2 (pt) | 2022-10-18 |
Family
ID=75252595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017578A BR112022017578A2 (pt) | 2020-03-27 | 2021-03-24 | Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230201185A1 (https=) |
| EP (2) | EP4125896B1 (https=) |
| JP (2) | JP2021155415A (https=) |
| KR (1) | KR20220157486A (https=) |
| CN (1) | CN115348863A (https=) |
| AU (1) | AU2021244918A1 (https=) |
| BR (1) | BR112022017578A2 (https=) |
| CA (1) | CA3176569A1 (https=) |
| ES (1) | ES3031577T3 (https=) |
| IL (1) | IL296694A (https=) |
| MX (1) | MX2022010811A (https=) |
| TW (1) | TWI823072B (https=) |
| WO (1) | WO2021191812A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20210341A (es) | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| CA3157525A1 (en) | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2021154796A1 (en) | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| PH12023552860A1 (en) | 2021-04-21 | 2024-05-20 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023182869A1 (en) * | 2022-03-25 | 2023-09-28 | Ildong Pharmaceutical Co., Ltd. | Novel salt of glp-1 receptor agonist compound, preparation method thereof and pharmaceutical composition comprising thereof |
| JP2025523949A (ja) * | 2022-07-22 | 2025-07-25 | ファイザー・インク | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンズイミダゾール－６－カルボン酸、１，３－ジヒドロキシ－２－（ヒドロキシメチル）プロパン－２－アミン塩を調製するための方法および中間体 |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| CN116675680B (zh) * | 2023-08-02 | 2023-10-20 | 药康众拓(北京)医药科技有限公司 | 一种氘代化合物及其制备方法、药物和应用 |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025224648A1 (en) * | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025252098A1 (zh) * | 2024-06-05 | 2025-12-11 | 杭州中美华东制药有限公司 | Glp-1受体激动剂的口服药物组合物及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE429217T1 (de) * | 2000-10-24 | 2009-05-15 | Ajinomoto Kk | Nateglinid enthaltende hydrophile arzneimittelpräparate |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| TWI538748B (zh) * | 2011-11-16 | 2016-06-21 | 鴻海精密工業股份有限公司 | 鏡頭除塵裝置 |
| WO2013117963A1 (en) * | 2012-02-09 | 2013-08-15 | Piramal Enterprises Limited | Stable oral tablet dosage form of an antidiabetic compound |
| SG10201805890QA (en) * | 2014-01-09 | 2018-08-30 | Verastem Inc | Compositions and methods for treatment of abnormal cell growth |
| JP5871294B1 (ja) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
| SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| MX2018011696A (es) * | 2016-03-31 | 2019-06-06 | Lupin Ltd | Composición farmacéutica de dapagliflozina. |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| EP3555064B9 (en) * | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
-
2021
- 2021-03-24 EP EP21714685.1A patent/EP4125896B1/en active Active
- 2021-03-24 BR BR112022017578A patent/BR112022017578A2/pt not_active Application Discontinuation
- 2021-03-24 AU AU2021244918A patent/AU2021244918A1/en not_active Abandoned
- 2021-03-24 US US17/906,651 patent/US20230201185A1/en not_active Abandoned
- 2021-03-24 JP JP2021049350A patent/JP2021155415A/ja not_active Ceased
- 2021-03-24 ES ES21714685T patent/ES3031577T3/es active Active
- 2021-03-24 IL IL296694A patent/IL296694A/en unknown
- 2021-03-24 KR KR1020227036905A patent/KR20220157486A/ko not_active Withdrawn
- 2021-03-24 EP EP24223164.5A patent/EP4537816A3/en active Pending
- 2021-03-24 WO PCT/IB2021/052430 patent/WO2021191812A1/en not_active Ceased
- 2021-03-24 MX MX2022010811A patent/MX2022010811A/es unknown
- 2021-03-24 CA CA3176569A patent/CA3176569A1/en active Pending
- 2021-03-24 TW TW110110639A patent/TWI823072B/zh not_active IP Right Cessation
- 2021-03-24 CN CN202180024485.6A patent/CN115348863A/zh active Pending
-
2025
- 2025-05-20 JP JP2025083688A patent/JP2025118943A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230201185A1 (en) | 2023-06-29 |
| IL296694A (en) | 2022-11-01 |
| JP2025118943A (ja) | 2025-08-13 |
| MX2022010811A (es) | 2022-09-27 |
| EP4537816A2 (en) | 2025-04-16 |
| WO2021191812A1 (en) | 2021-09-30 |
| TWI823072B (zh) | 2023-11-21 |
| JP2021155415A (ja) | 2021-10-07 |
| EP4125896B1 (en) | 2025-05-07 |
| EP4125896A1 (en) | 2023-02-08 |
| EP4537816A3 (en) | 2025-06-25 |
| CA3176569A1 (en) | 2021-09-30 |
| CN115348863A (zh) | 2022-11-15 |
| ES3031577T3 (en) | 2025-07-09 |
| AU2021244918A1 (en) | 2022-09-29 |
| TW202202139A (zh) | 2022-01-16 |
| KR20220157486A (ko) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017578A2 (pt) | Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo | |
| Chatzianastasiou et al. | Cardioprotection by H2S donors: nitric oxide-dependent and‑independent mechanisms | |
| Yalin et al. | Strontium ranelate treatment improves oxidative damage in osteoporotic rat model | |
| BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
| BR112024002129A2 (pt) | Formas sólidas de ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico, sal de 1,3-di-hidróxi-2-(hidroximetil)propan-2-amina | |
| BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
| BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| BR112016013734A2 (pt) | Composto, composição farmacêutica, kit, e uso de um composto | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| BR112021021224A2 (pt) | Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112014016808A2 (pt) | composições de biguanida e métodos de tratamento de distúrbios metabólicos | |
| BR112022024156A2 (pt) | Compostos heterocílicos antelmínticos | |
| BR112013027241A2 (pt) | "composto inibidor de rock, composição que o compreende e seus usos" | |
| BR112013027034A2 (pt) | "composições farmacêuticas compreendendo enzimas digestivas e seu uso". | |
| BR112015020600A2 (pt) | composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição | |
| BR112016014042A2 (pt) | composições e métodos para tratar deposição de tecido adiposo | |
| BR112021022965A2 (pt) | Composições que compreendem ácidos graxos cetilados e uso das mesmas no tratamento de artrite e condições articulares inflamatórias | |
| BRPI0516454A (pt) | compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii | |
| ES2701675T3 (es) | Irisina para el cuidado y la prevención de la osteoporosis | |
| BR112012020060A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero. | |
| AR129415A1 (es) | Tratamiento de diabetes de tipo 2 o control del peso con ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico o una sal farmacéutica de este | |
| EP1972342A1 (en) | Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: PFIZER INC. (US) |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |